The Sunday biotech signal
A pulmonary readout nears. Sunday hiring expands.
Pulmovant sets a September 8 Phase 2 evidence checkpoint while 406 active biopharma opportunities added before cutoff lift Sunday volume 78.9%.
JobReports original editorial image
406
Active biopharma jobs added
23
Biopharma employers
+78.9%
Versus last Sunday
54
Commercial & business roles
This dated issue is part of the public report archive. See the service update for account availability.
Pulmonary hypertension / Phase 2
Pulmovant schedules PHocus topline results for September 8
Pulmovant, a Roivant company, said it will present topline results from the Phase 2 PHocus study of mosliciguat at the European Respiratory Society Congress on September 8 at 6:15 AM Eastern.
PHocus is a randomized, double-blind, placebo-controlled study in 135 adults with pulmonary hypertension associated with interstitial lung disease. Mosliciguat is an investigational inhaled soluble guanylate cyclase activator. The announcement did not disclose the direction, magnitude, or statistical significance of the results.
Why it matters
The scheduled presentation creates a defined evidence checkpoint in a serious cardiopulmonary condition. Until the data are shown, conclusions about efficacy, safety, or the program's next step would be premature.
Sunday additions rise sharply
JobReports added 406 active biotechnology and pharmaceutical opportunities from 23 employers between midnight Eastern and today's cutoff. That is 78.9% above the comparable Sunday window one week earlier. Commercial and business roles were the largest named family, followed by research and laboratory work.
These are active opportunities first captured by JobReports before cutoff, not employer-supplied posting times. Role-family and location classifications are directional. The hiring sample is independent of today's news announcement and does not imply the companies below created these jobs today.
14
Rahway roles
12
U.S.-remote roles
8
Cambridge roles
Editor's shortlist
Five roles worth a closer look
Manufacturing Associate, NGS TE Production
South San Francisco, California
Clinical Trial Specialist
Cincinnati, Ohio or Santa Clara, California · Onsite
Process Manager, Upstream Process Development
Milford, Massachusetts
Director, US Advertising and Promotion, Global Regulatory Affairs
Morristown, New Jersey or Cambridge, Massachusetts
Patient Support & Advocacy Navigator
United States · Remote
The takeaway
One evidence deadline. A broad execution market.
The weekend news cycle produced one qualifying program signal, and its substance arrives Tuesday. The hiring picture is already wider: today's verified roles span molecular production, clinical trials, process development, regulatory promotion review, and patient support.